Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in J Thorac Cardiovasc Surg Retrieve available abstracts of 126 articles: HTML format

Single Articles

February 2023
1. COOLEY-RIEDERS K, Glenn C, Van Haren RM, Salfity H, et al
   A decade of surgical outcomes in a structured lung cancer screening program.
   J Thorac Cardiovasc Surg. 2023 Feb 4:S0022-5223(23)00097.
   PubMed     Abstract available
   
   
   
2. GAUTHIER JM, Kozower BD
   Commentary: Stereotactic body radiation therapy utilization emits answers to the volume-outcome relationship.
   J Thorac Cardiovasc Surg. 2023;165:480-481.
   PubMed    
   
   
   January 2023
3. LEE JM, Vallieres E, Ding B, Johnson A, et al
   Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial.
   J Thorac Cardiovasc Surg. 2023 Jan 21:S0022-5223(23)00080.
   PubMed     Abstract available
   
   
   
4. LANUTI M
   Commentary: Evolution of the preoperative space: Neoadjuvant targeted therapy in patients with operable non-small cell lung cancer with actionable mutations ... Surgeon equipoise?
   J Thorac Cardiovasc Surg. 2023 Jan 7:S0022-5223(23)00005.
   PubMed    
   
   
   
5. GILES AE, Cassivi SD
   Commentary: Lest we biopsy: Positron emission tomography-computed tomography as a tool to achieve a "greater good" in the diagnosis and management of the resectable anterior mediastinal mass.
   J Thorac Cardiovasc Surg. 2023;165:382-383.
   PubMed    
   
   
   
6. RIPLEY RT, Mansfield AS, Sepesi B, Bueno R, et al
   Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy.
   J Thorac Cardiovasc Surg. 2023;165:364-368.
   PubMed    
   
   
   December 2022
7. MARMOR HN, Kammer MN, Deppen SA, Shipe M, et al
   Improving lung cancer diagnosis with cancer, fungal, and imaging biomarkers.
   J Thorac Cardiovasc Surg. 2022 Dec 23:S0022-5223(22)01354.
   PubMed     Abstract available
   
   
   
8. MATHEY-ANDREWS C, McCarthy M, Potter AL, Beqari J, et al
   Safety and feasibility of minimally invasive lobectomy after neoadjuvant immunotherapy for non-small cell lung cancer.
   J Thorac Cardiovasc Surg. 2022 Dec 16:S0022-5223(22)01342.
   PubMed     Abstract available
   
   
   
9. DUAN X, Yang Z, Hao X, Zhou S, et al
   Early ligation of the pulmonary vein can reduce the dissemination of shed tumor cells during thoracoscopic lobectomy.
   J Thorac Cardiovasc Surg. 2022;164:1623-1635.
   PubMed     Abstract available
   
   
   November 2022
10. LENGEL HB, Zheng J, Tan KS, Liu CC, et al
    Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Nov 17:S0022-5223(22)01246.
    PubMed     Abstract available
    
    
    
11. BROWNLEE AR, Soukiasian HJ
    Commentary: Minimally invasive lobectomy for lung cancer: Safely finishing what you started.
    J Thorac Cardiovasc Surg. 2022 Nov 12:S0022-5223(22)01237.
    PubMed    
    
    
    
12. ERWIN P, Donington J
    Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Nov 4:S0022-5223(22)01170.
    PubMed    
    
    
    
13. TSITSIAS T, Yasufuku K, Pierre A, Leighl N, et al
    Influence of anterior tumor location on survival after resection of lung cancer invading the thoracic inlet (Pancoast tumors).
    J Thorac Cardiovasc Surg. 2022 Nov 2:S0022-5223(22)01154.
    PubMed     Abstract available
    
    
    
14. LAPIDOT M, Mazzola E, Bueno R
    Outcomes of pleurectomy decortication in patients with biphasic mesothelioma.
    J Thorac Cardiovasc Surg. 2022;164:1340-1348.
    PubMed     Abstract available
    
    
    
15. FRIEDBERG JS
    Commentary: "Can we" versus "should we": The defining dilemma of mesothelioma surgery.
    J Thorac Cardiovasc Surg. 2022;164:1349-1350.
    PubMed    
    
    
    
16. TSUTANI Y, Ito M, Shimada Y, Ito H, et al
    The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;164:1306-1315.
    PubMed     Abstract available
    
    
    October 2022
17. ALTORKI NK, Villena-Vargas J
    Commentary: Neoadjuvant immune checkpoint monotherapy for lung cancer: Has the train left the station?
    J Thorac Cardiovasc Surg. 2022 Oct 30:S0022-5223(22)01152.
    PubMed    
    
    
    
18. KALATA S, Lam GT, Alnajjar RM, Clark MJ, et al
    Adequate lung cancer surgery lymphadenectomy within a statewide quality collaborative: Quality improvement in action.
    J Thorac Cardiovasc Surg. 2022 Oct 28:S0022-5223(22)01150.
    PubMed     Abstract available
    
    
    
19. PREDINA J, Suliman R, Potter AL, Panda N, et al
    Postoperative radiotherapy with modern techniques does not improve survival for operable stage IIIA-N2 non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Oct 18:S0022-5223(22)01134.
    PubMed     Abstract available
    
    
    
20. RUSCH VW, Nicholas A, Patterson GA, Waqar SN, et al
    Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lun
    J Thorac Cardiovasc Surg. 2022 Oct 8. pii: S0022-5223(22)01055.
    PubMed     Abstract available
    
    
    September 2022
21. SAKOWITZ S, Verma A, Mabeza RM, Cho NY, et al
    Clinical and financial outcomes of pulmonary resection for lung cancer in safety-net hospitals.
    J Thorac Cardiovasc Surg. 2022 Sep 27. pii: S0022-5223(22)01026.
    PubMed     Abstract available
    
    
    
22. QIU B, Ji Y, Zhang F, Bai G, et al
    Outcomes and experience of anatomical partial lobectomy.
    J Thorac Cardiovasc Surg. 2022;164:637-647.
    PubMed     Abstract available
    
    
    
23. ZHANG Y, Chen H
    Commentary: Anatomical partial lobectomy: The indications should be better defined.
    J Thorac Cardiovasc Surg. 2022;164:648-649.
    PubMed    
    
    
    August 2022
24. HASHIMOTO K, Ariyasu R, Ichinose J, Matsuura Y, et al
    Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.
    J Thorac Cardiovasc Surg. 2022 Aug 25. pii: S0022-5223(22)00903.
    PubMed     Abstract available
    
    
    
25. LEE B, Mynard N, Nasar A, Villena-Vargas J, et al
    Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: Results from a randomized trial.
    J Thorac Cardiovasc Surg. 2022 Aug 6. pii: S0022-5223(22)00804.
    PubMed     Abstract available
    
    
    
26. TILL BM, Mack S, Whitehorn G, Rahman U, et al
    Impact of stereotactic body radiation therapy volume on surgical patient selection, short-term survival, and long-term survival in early-stage non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Aug 6. pii: S0022-5223(22)00816.
    PubMed     Abstract available
    
    
    
27. LOGAN CD, Jacobs RC, Feinglass J, Lung K, et al
    National trends in the quality of segmentectomy for lung cancer.
    J Thorac Cardiovasc Surg. 2022 Aug 5. pii: S0022-5223(22)00821.
    PubMed     Abstract available
    
    
    
28. LEE JM
    Commentary: The search for a chemotherapy-free immunotherapy regimen in resectable non-small cell lung cancer: The unmet need.
    J Thorac Cardiovasc Surg. 2022 Aug 3. pii: S0022-5223(22)00807.
    PubMed    
    
    
    
29. DELMAN AM, Turner KM, Wima K, Simon VE, et al
    Offering lung resection to current smokers: An opportunity for more equitable care.
    J Thorac Cardiovasc Surg. 2022;164:400-408.
    PubMed     Abstract available
    
    
    July 2022
30. KHO J, Mitchell J, Curry N, Di Chiara F, et al
    Should all patients receive extended thromboprophylaxis after resection of primary lung cancer?
    J Thorac Cardiovasc Surg. 2022 Jul 5. pii: S0022-5223(22)00712.
    PubMed     Abstract available
    
    
    
31. LI D, Deng C, Wang S, Li Y, et al
    Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative.
    J Thorac Cardiovasc Surg. 2022 Jul 5. pii: S0022-5223(22)00713.
    PubMed     Abstract available
    
    
    
32. SULLIVAN KA, Farrokhyar F, Leontiadis GI, Patel YS, et al
    Routine systematic sampling versus targeted sampling during endobronchial ultrasound: A randomized feasibility trial.
    J Thorac Cardiovasc Surg. 2022;164:254-261.
    PubMed     Abstract available
    
    
    
33. LIN J
    Commentary: Teach me to fish-spears, rods, and nets: Lymph node sampling during endobronchial ultrasound.
    J Thorac Cardiovasc Surg. 2022;164:263-264.
    PubMed    
    
    
    
34. NA KJ, Kim YT
    Commentary: Targeted sampling during endobronchial ultrasound: Additional prerequisites for clinical implementation.
    J Thorac Cardiovasc Surg. 2022;164:262-263.
    PubMed    
    
    
    
35. SATO M, Kobayashi M, Sakamoto J, Fukai R, et al
    The role of virtual-assisted lung mapping 2.0 combining microcoils and dye marks in deep lung resection.
    J Thorac Cardiovasc Surg. 2022;164:243-251.
    PubMed     Abstract available
    
    
    June 2022
36. RUSCH VW
    Commentary: Surgical standardization in mesothelioma trials.
    J Thorac Cardiovasc Surg. 2022;163:1949-1950.
    PubMed    
    
    
    
37. GIFFIN C, Kidane B
    Commentary: Less is maybe more: Sublobar resection in screen-detected lung cancers.
    J Thorac Cardiovasc Surg. 2022;163:1917-1918.
    PubMed    
    
    
    
38. HASEGAWA S, Yokoi K, Okada M, Tanaka F, et al
    Neoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2022;163:1940-1947.
    PubMed     Abstract available
    
    
    
39. GRIFFIN CM, van Berkel VH
    Commentary: A return trip to MARS: Less may be more when treating mesothelioma.
    J Thorac Cardiovasc Surg. 2022;163:1948-1949.
    PubMed    
    
    
    May 2022
40. LIN J
    Commentary: Maximum standardized uptake value is no crystal ball for candidate selection for sublobar resection: The future is cloudy (ground-glass).
    J Thorac Cardiovasc Surg. 2022;163:1667-1668.
    PubMed    
    
    
    
41. GILES AE, Kidane B
    Commentary: Toward precision surgery: Advances in defining sublobar resection candidacy.
    J Thorac Cardiovasc Surg. 2022;163:1666-1667.
    PubMed    
    
    
    
42. MURAOKA Y, Yoshida Y, Nakagawa K, Ito K, et al
    Maximum standardized uptake value of the primary tumor does not improve candidate selection for sublobar resection.
    J Thorac Cardiovasc Surg. 2022;163:1656-1665.
    PubMed     Abstract available
    
    
    
43. ABDALLAH HM, Martinez-Meehan D, Lutfi W, Dhupar R, et al
    Adjuvant chemotherapy for pulmonary sarcomatoid carcinoma: A retrospective analysis of the National Cancer Database.
    J Thorac Cardiovasc Surg. 2022;163:1669-1681.
    PubMed     Abstract available
    
    
    April 2022
44. FURRER K, Weder W, Eboulet EI, Betticher D, et al
    Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
    J Thorac Cardiovasc Surg. 2022 Apr 18. pii: S0022-5223(22)00403.
    PubMed     Abstract available
    
    
    
45. THOMAS PA
    Commentary: Challenging the final frontier of lung transplantation.
    J Thorac Cardiovasc Surg. 2022 Apr 9. pii: S0022-5223(22)00400.
    PubMed    
    
    
    
46. STARNES SL
    Commentary: Artificial intelligence for pulmonary nodules: Machines to diagnosis cancer.
    J Thorac Cardiovasc Surg. 2022;163:1506-1507.
    PubMed    
    
    
    
47. ASHRAF SF, Yin K, Meng CX, Wang Q, et al
    Predicting benign, preinvasive, and invasive lung nodules on computed tomography scans using machine learning.
    J Thorac Cardiovasc Surg. 2022;163:1496-1505.
    PubMed     Abstract available
    
    
    
48. KNEUERTZ PJ, Yudovich MS, Amadi CC, Bashian E, et al
    Pulmonary artery size on computed tomography is associated with major morbidity after pulmonary lobectomy.
    J Thorac Cardiovasc Surg. 2022;163:1521-1529.
    PubMed     Abstract available
    
    
    
49. EKEKE CN, Russell KL, Murthy P, Guo ZS, et al
    Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
    J Thorac Cardiovasc Surg. 2022;163:e313-e328.
    PubMed     Abstract available
    
    
    March 2022
50. ISHIWATA T, Motooka Y, Ujiie H, Inage T, et al
    Endobronchial ultrasound-guided bipolar radiofrequency ablation for lung cancer: A first-in-human clinical trial.
    J Thorac Cardiovasc Surg. 2022 Mar 26. pii: S0022-5223(22)00344.
    PubMed     Abstract available
    
    
    
51. CHIDI AP, Broderick SR
    Commentary: Perioperative systemic therapy in early-stage non-small cell lung cancer: The future is bright.
    J Thorac Cardiovasc Surg. 2022 Mar 24. pii: S0022-5223(22)00345.
    PubMed    
    
    
    
52. HEIDEN BT, Subramanian MP, Liu J, Keith A, et al
    Long-term patient-reported outcomes after non-small cell lung cancer resection.
    J Thorac Cardiovasc Surg. 2022 Mar 12. pii: S0022-5223(22)00270.
    PubMed     Abstract available
    
    
    
53. ELKIN PL, Mullin S, Tetewsky S, Resendez SD, et al
    Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Mar 10. pii: S0022-5223(22)00241.
    PubMed     Abstract available
    
    
    
54. LIN J
    Commentary: Reading the voxels: A fortune teller's nomogram to invasiveness in stage IA lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:816-817.
    PubMed    
    
    
    
55. BRUNELLI A
    Commentary: Ground glass opacity: Is it the Holy Grail?
    J Thorac Cardiovasc Surg. 2022;163:802-803.
    PubMed    
    
    
    
56. QIU ZB, Zhang C, Chu XP, Cai FY, et al
    Quantifying invasiveness of clinical stage IA lung adenocarcinoma with computed tomography texture features.
    J Thorac Cardiovasc Surg. 2022;163:805-815.
    PubMed     Abstract available
    
    
    
57. VILLENA-VARGAS J, Lutton EM, Mynard N, Nasar A, et al
    Safety of lung cancer surgery during COVID-19 in a pandemic epicenter.
    J Thorac Cardiovasc Surg. 2022 Mar 1. pii: S0022-5223(22)00222.
    PubMed     Abstract available
    
    
    February 2022
58. ALTORKI N, Villena-Vargas J, Wakelee H
    Adjuvant therapy for early-stage non-small cell lung cancer: The breaking of a new dawn.
    J Thorac Cardiovasc Surg. 2022 Feb 17. pii: S0022-5223(22)00202.
    PubMed    
    
    
    
59. CASTRO PP, de Perrot M, Chua YC, Bezjak A, et al
    Importance of tumor size in resectable stage III-N2 non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Feb 11. pii: S0022-5223(22)00195.
    PubMed     Abstract available
    
    
    
60. STILES BM
    Commentary: Early stage epidermal growth factor receptor lung cancer: Skip to the good stuff?
    J Thorac Cardiovasc Surg. 2022 Feb 5. pii: S0022-5223(22)00125.
    PubMed    
    
    
    
61. GRAY KD, Molena D
    Commentary: To cut is a chance to cure? Lessons to be learned from the PulMiCC trial.
    J Thorac Cardiovasc Surg. 2022;163:493-494.
    PubMed    
    
    
    
62. VAN RAEMDONCK D, Van Cutsem E
    Commentary: A crusade against current pulmonary metastasectomy practice in colorectal cancer patients: Do the con arguments remain after the PulMiCC trial?
    J Thorac Cardiovasc Surg. 2022;163:491-492.
    PubMed    
    
    
    
63. ALTORKI N, Vimolratana M
    Commentary: Surgery for ground-glass nodules: Free lunch or slippery slope?
    J Thorac Cardiovasc Surg. 2022;163:465-466.
    PubMed    
    
    
    
64. PASS HI
    Commentary: Pulmonary metastasectomy efficacy: A game of clones?
    J Thorac Cardiovasc Surg. 2022;163:503-510.
    PubMed    
    
    
    
65. BLUMENTHALER AN, Antonoff MB
    Commentary: The best outcomes for pulmonary metastasectomy come from picking the right patients.
    J Thorac Cardiovasc Surg. 2022;163:483-484.
    PubMed    
    
    
    
66. TREASURE T, Dunning J, Williams NR, Macbeth F, et al
    Lung metastasectomy for colorectal cancer: The impression of benefit from uncontrolled studies was not supported in a randomized controlled trial.
    J Thorac Cardiovasc Surg. 2022;163:486-490.
    PubMed    
    
    
    
67. ZHANG Y, Ma X, Shen X, Wang S, et al
    Surgery for pre- and minimally invasive lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:456-464.
    PubMed     Abstract available
    
    
    
68. LIU Z, Yin J, Zhou Q, Yang J, et al
    Survival after pulmonary metastasectomy for relapsed osteosarcoma.
    J Thorac Cardiovasc Surg. 2022;163:469-479.
    PubMed     Abstract available
    
    
    
69. MATSUURA Y, Ninomiya H, Ichinose J, Nakao M, et al
    Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase-rearranged lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:441-451.
    PubMed     Abstract available
    
    
    January 2022
70. SEPESI B, Zhou N, William WN Jr, Lin HY, et al
    Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2022 Jan 23. pii: S0022-5223(22)00089.
    PubMed     Abstract available
    
    
    
71. WATANABE I, Hattori A, Fukui M, Matsunaga T, et al
    Pulmonary artery reconstruction for non-small cell lung cancer: Surgical management and long-term outcomes.
    J Thorac Cardiovasc Surg. 2022 Jan 22. pii: S0022-5223(22)00087.
    PubMed     Abstract available
    
    
    
72. LANUTI M
    Commentary: Induction antiangiogenesis for stage IIIA-N2 non-small cell lung cancer is not the answer yet: Optimal induction for operable disease is a clear work in progress.
    J Thorac Cardiovasc Surg. 2022 Jan 8. pii: S0022-5223(22)00007.
    PubMed    
    
    
    
73. LAZAR JF, Herrera LJ
    Commentary: Ablation and endobronchial ultrasound for treating early lung cancer: Two great technologies that may work great together!
    J Thorac Cardiovasc Surg. 2022 Jan 8. pii: S0022-5223(22)00009.
    PubMed    
    
    
    
74. LINDEN PA
    Commentary: Spread the news: Spread through air spaces matters.
    J Thorac Cardiovasc Surg. 2022;163:285.
    PubMed    
    
    
    
75. LIN J
    Commentary: Should we start spreading the news? Prognostic influence of spread through air spaces in early-stage lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:286-287.
    PubMed    
    
    
    
76. DAVID EA
    Commentary: STAS is here to STAY.
    J Thorac Cardiovasc Surg. 2022;163:287-288.
    PubMed    
    
    
    
77. ZHANG Y, Chen H
    Commentary: Is sublobar resection enough for ground-glass opacity-dominant lung adenocarcinoma?
    J Thorac Cardiovasc Surg. 2022;163:303-304.
    PubMed    
    
    
    
78. ZHANG Y, Cao Y, Li H
    REPLY: THE CONTINUED DEBATE ON ROBOTIC SEGMENTECTOMY-AGREE TO DISAGREE.
    J Thorac Cardiovasc Surg. 2022;163:e99-e100.
    PubMed    
    
    
    
79. JUNG W, Chung JH, Yum S, Kim K, et al
    The differential prognostic impact of spread through air spaces in early-stage lung adenocarcinoma after lobectomy according to the pT descriptor.
    J Thorac Cardiovasc Surg. 2022;163:277-284.
    PubMed     Abstract available
    
    
    
80. CORSINI EM, Ripley RT
    Commentary: KRAS-mutant lung adenocarcinomas-a work in progress.
    J Thorac Cardiovasc Surg. 2022;163:e87-e88.
    PubMed    
    
    
    
81. MA Z, Zhang Y, Deng C, Fu F, et al
    The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
    J Thorac Cardiovasc Surg. 2022;163:e73-e85.
    PubMed     Abstract available
    
    
    December 2021
82. CONNOLLY JG, Fiasconaro M, Tan KS, Cirelli MA Jr, et al
    Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Dec 23. pii: S0022-5223(21)01818.
    PubMed     Abstract available
    
    
    
83. TAKAMOCHI K, Suzuki K, Tsuboi M, Niho S, et al
    Randomized phase II trial of pemetrexed-cisplatin plus bevacizumab or thoracic radiotherapy followed by surgery for stage IIIA (N2) nonsquamous non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Dec 9. pii: S0022-5223(21)01714.
    PubMed     Abstract available
    
    
    
84. SAVITCH SL, Grenda TR, Yi M, Till B, et al
    Facility-level national trends in racial disparities of surgical therapy for early-stage lung cancer.
    J Thorac Cardiovasc Surg. 2021 Dec 9. pii: S0022-5223(21)01716.
    PubMed     Abstract available
    
    
    
85. ARNOLD BN, Antonoff MB
    Commentary: Optimizing resources in lung cancer survivorship.
    J Thorac Cardiovasc Surg. 2021 Dec 4. pii: S0022-5223(21)01691.
    PubMed    
    
    
    
86. CHEN J, Soultanis KM, Sun F, Gonzalez-Rivas D, et al
    Outcomes of sleeve lobectomy versus pneumonectomy: A propensity score-matched study.
    J Thorac Cardiovasc Surg. 2021;162:1619-1628.
    PubMed     Abstract available
    
    
    November 2021
87. SHENOY R, Okereke I
    Commentary: Lung cancer resections during the pandemic.
    J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01651.
    PubMed    
    
    
    
88. CHANG SH
    Commentary: Surgery versus stereotactic body radiation therapy for patients with renal dysfunction and non-small cell lung cancer: The answer is still not clear.
    J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01647.
    PubMed    
    
    
    
89. KESHAVA HB, Tan KS, Dycoco J, Huang J, et al
    Long-term assessment of efficacy with a novel thoracic survivorship program for patients with lung cancer.
    J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01635.
    PubMed     Abstract available
    
    
    October 2021
90. POULSON MR, Kenzik KM, Singh S, Pavesi F, et al
    Redlining, structural racism, and lung cancer screening disparities.
    J Thorac Cardiovasc Surg. 2021 Oct 14. pii: S0022-5223(21)01421.
    PubMed     Abstract available
    
    
    
91. HANNA WC
    Commentary: Wedge versus segmentectomy-It is best to err on the side of caution.
    J Thorac Cardiovasc Surg. 2021;162:1254.
    PubMed    
    
    
    September 2021
92. DELMAN AM, Van Haren RM
    Commentary: Mitigating lung cancer mortality in patients with end-stage renal disease.
    J Thorac Cardiovasc Surg. 2021 Sep 27. pii: S0022-5223(21)01389.
    PubMed    
    
    
    
93. SAITO T, Murakawa T, Shintani Y, Okami J, et al
    Preoperative renal dysfunction and long-term survival after surgery for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Sep 10. pii: S0022-5223(21)01311.
    PubMed     Abstract available
    
    
    
94. FARMER DM, Ripley RT
    Commentary: EGFR mutations lung adenocarcinoma-Is the driver removed with the lobe?
    J Thorac Cardiovasc Surg. 2021;162:675-676.
    PubMed    
    
    
    
95. KHORFAN R, Cooke DT, Meguid RA, Backhus L, et al
    Institutional factors associated with adherence to quality measures for stage I and II non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021;162:649-660.
    PubMed     Abstract available
    
    
    
96. DENG C, Zhang Y, Ma Z, Fu F, et al
    Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2021;162:664-674.
    PubMed     Abstract available
    
    
    August 2021
97. BRUNELLI A
    Commentary: Lobectomy should be the exception rather than the rule to resect screen-detected stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Aug 27. pii: S0022-5223(21)01253.
    PubMed    
    
    
    
98. EGYUD M, Burt BM
    Commentary: The structure of structural racism revealed by lung cancer screening.
    J Thorac Cardiovasc Surg. 2021 Aug 24. pii: S0022-5223(21)01248.
    PubMed    
    
    
    
99. SIENICKI E, Onaitis M
    Commentary: New players in epidermal growth factor receptor tyrosine kinase inhibitor resistance.
    J Thorac Cardiovasc Surg. 2021;162:474-475.
    PubMed    
    
    
    
100. FU F, Zhang Y, Wang S, Li Y, et al
     Computed tomography density is not associated with pathological tumor invasion for pure ground-glass nodules.
     J Thorac Cardiovasc Surg. 2021;162:451-459.
     PubMed     Abstract available
     
     
     
101. YOSHIYASU N, Kojima F, Hayashi K, Bando T, et al
     Radiomics technology for identifying early-stage lung adenocarcinomas suitable for sublobar resection.
     J Thorac Cardiovasc Surg. 2021;162:477-485.
     PubMed     Abstract available
     
     
     July 2021
102. PENNATHUR A, Brunelli A, Criner G, Keshavarz H, et al
     Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document.
     J Thorac Cardiovasc Surg. 2021 Jul 29. pii: S0022-5223(21)01129.
     PubMed     Abstract available
     
     
     
103. CHUDGAR NP, Stiles BM
     Commentary: Adjuvant therapy in resected T1 2N0 non-small cell lung cancer: Surgeons should lead.
     J Thorac Cardiovasc Surg. 2021 Jul 14. pii: S0022-5223(21)01036.
     PubMed    
     
     
     
104. WOODARD GA, Li A, Boffa DJ
     Role of adjuvant therapy in T1-2N0 resected non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 Jul 10. pii: S0022-5223(21)01032.
     PubMed    
     
     
     
105. WANG SX, Marshall MB
     Commentary: A new hope: Do ADAURA trial results change the paradigm for treatment of resectable lung adenocarcinoma?
     J Thorac Cardiovasc Surg. 2021;162:293-294.
     PubMed    
     
     
     
106. ANTONOFF MB, Morris VK
     Reply from author: Biology is king, but metastasectomy still has a role for properly selected patients.
     J Thorac Cardiovasc Surg. 2021;162:e136-e138.
     PubMed    
     
     
     
107. CAMERON RB
     Reply: Discussions regarding pulmonary metastasectomy are similar to American politics: Both are extremely polarizing, unsatisfying, inconclusive, and undertaken at your own peril.
     J Thorac Cardiovasc Surg. 2021;162:e135-e136.
     PubMed    
     
     
     
108. HIRPARA DH, Kidane B
     Commentary: VATS, RATS, stats, and some caveats.
     J Thorac Cardiovasc Surg. 2021;162:269-270.
     PubMed    
     
     
     
109. SIHAG S
     Commentary: Sarcomas and sarcomatoid tumors of the lung...not your average lung cancers.
     J Thorac Cardiovasc Surg. 2021;162:285-286.
     PubMed    
     
     
     
110. JONES DR, Wu YL, Tsuboi M, Herbst RS, et al
     Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.
     J Thorac Cardiovasc Surg. 2021;162:288-292.
     PubMed    
     
     
     
111. CORSINI EM, Mitchell KG, Correa A, Morris VK, et al
     Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy.
     J Thorac Cardiovasc Surg. 2021;162:296-305.
     PubMed     Abstract available
     
     
     
112. ROBINSON LA, Babacan NA, Tanvetyanon T, Henderson-Jackson E, et al
     Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas.
     J Thorac Cardiovasc Surg. 2021;162:274-284.
     PubMed     Abstract available
     
     
     
113. KAMEL MK, Lee B, Harrison SW, Port JL, et al
     Sublobar resection is comparable to lobectomy for screen-detected lung cancer.
     J Thorac Cardiovasc Surg. 2021 Jul 1. pii: S0022-5223(21)01011.
     PubMed     Abstract available
     
     
     May 2021
114. ISBELL JM, Li BT, Gomez DR
     The emerging role of local therapy in oligometastatic non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 May 29. pii: S0022-5223(21)00875.
     PubMed    
     
     
     
115. DONINGTON JS
     Commentary: Why do we operate in metastatic lung cancer?
     J Thorac Cardiovasc Surg. 2021 May 8. pii: S0022-5223(21)00771.
     PubMed    
     
     
     
116. WIGHTMAN SC, Kim AW
     Commentary: When less is more for lung cancers.
     J Thorac Cardiovasc Surg. 2021;161:1650-1651.
     PubMed    
     
     
     
117. CERFOLIO RJ
     Commentary: Let us raise the bar higher for better patient outcomes.
     J Thorac Cardiovasc Surg. 2021;161:1649-1650.
     PubMed    
     
     
     
118. WEKSLER B, Sullivan JL, Schumacher LY
     Randomized trial of bupivacaine with epinephrine versus bupivacaine liposome suspension in patients undergoing minimally invasive lung resection.
     J Thorac Cardiovasc Surg. 2021;161:1652-1661.
     PubMed     Abstract available
     
     
     April 2021
119. FERNANDEZ R, Ahmad U
     Commentary: A new hope-neoadjuvant immunotherapy for resectable non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 Apr 27. pii: S0022-5223(21)00740.
     PubMed    
     
     
     
120. BONNER SN, Wakeam E
     The volume-outcome relationship in lung cancer surgery: The impact of the social determinants of health care delivery.
     J Thorac Cardiovasc Surg. 2021 Apr 20. pii: S0022-5223(21)00593.
     PubMed    
     
     
     
121. TONG BC, Gu L, Wang X, Wigle DA, et al
     Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 Apr 9. pii: S0022-5223(21)00583.
     PubMed     Abstract available
     
     
     
122. HOD T, Freedberg KJ, Motwani SS, Chen M, et al
     Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma.
     J Thorac Cardiovasc Surg. 2021;161:1510-1518.
     PubMed     Abstract available
     
     
     March 2021
123. ELY S, Jiang SF, Dominguez DA, Patel AR, et al
     Effect of thoracic surgery regionalization on long-term survival after lung cancer resection.
     J Thorac Cardiovasc Surg. 2021 Mar 20. pii: S0022-5223(21)00530.
     PubMed     Abstract available
     
     
     
124. ANTONOFF MB, Sofocleous CT, Callstrom MR, Nguyen QN, et al
     The roles of surgery, stereotactic radiation, and ablation for treatment of pulmonary metastases.
     J Thorac Cardiovasc Surg. 2021 Mar 6. pii: S0022-5223(21)00423.
     PubMed    
     
     
     
125. DONAHOE LL, Nason GJ, Bedard PL, Hansen AR, et al
     Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest.
     J Thorac Cardiovasc Surg. 2021;161:856-868.
     PubMed     Abstract available
     
     
     
126. SHEMANSKI KA, Farias A, Lieu D, Kim AW, et al
     Understanding thoracic surgeons' perceptions of administrative database analyses and guidelines in clinical decision-making.
     J Thorac Cardiovasc Surg. 2021;161:807-816.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: